Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	115
Overall Study	STARTED	Reldesemtiv 150 mg Twice Daily	113
Overall Study	STARTED	Reldesemtiv 300 mg Twice Daily	113
Overall Study	STARTED	Reldesemtiv 450 mg Twice Daily	117
Overall Study	COMPLETED	Placebo	95
Overall Study	COMPLETED	Reldesemtiv 150 mg Twice Daily	100
Overall Study	COMPLETED	Reldesemtiv 300 mg Twice Daily	97
Overall Study	COMPLETED	Reldesemtiv 450 mg Twice Daily	98
Overall Study	NOT COMPLETED	Placebo	20
Overall Study	NOT COMPLETED	Reldesemtiv 150 mg Twice Daily	13
Overall Study	NOT COMPLETED	Reldesemtiv 300 mg Twice Daily	16
Overall Study	NOT COMPLETED	Reldesemtiv 450 mg Twice Daily	19

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03160898/flow